Ryouichi Tsunedomi

Title: Ryouichi Tsunedomi: Innovator in Pharmacogenomics

Introduction

Ryouichi Tsunedomi is a notable inventor based in Ube, Japan, recognized for his contributions to the field of pharmacogenomics. With a total of five patents to his name, Tsunedomi has made significant strides in predicting drug responses and side effects, particularly in cancer treatment.

Latest Patents

One of Tsunedomi's latest patents is a method for assisting the prediction of the risk of occurrence of side effects of irinotecan. This invention aims to provide a simple and efficient device for predicting such risks by analyzing single nucleotide polymorphisms in specific genes. The method focuses on genes such as APCDD1L, R3HCC1, OR51I2, MKKS, EDEM3, and ACOX1, which are present in genomic DNA from biological samples collected from test subjects. Another significant patent involves a method for determining the pharmacokinetics of axitinib and predicting its therapeutic effect based on these pharmacokinetics. This invention allows for the convenient calculation of predicted pharmacokinetic parameters using specific gene polymorphisms and background factors related to the test subject.

Career Highlights

Throughout his career, Ryouichi Tsunedomi has worked with prominent organizations, including Toyo Kohan Co., Ltd. and Yamaguchi University. His work has focused on enhancing the understanding of drug interactions and improving patient outcomes through personalized medicine.

Collaborations

Tsunedomi has collaborated with esteemed colleagues such as Shoichi Hazama and Shuichi Kamei, contributing to advancements in pharmacogenomics and drug development.

Conclusion

Ryouichi Tsunedomi's innovative work in pharmacogenomics has the potential to transform cancer treatment by enabling more accurate predictions of drug responses and side effects. His contributions are paving the way for personalized medicine, ultimately improving patient care and outcomes.